ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00728949
Recruitment Status : Completed
First Posted : August 6, 2008
Last Update Posted : March 20, 2015
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2012
  Actual Study Completion Date : February 2015
  Certification/Extension First Submitted : September 14, 2010

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 March 17, 2018 April 17, 2018